Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Détails
ID Serval
serval:BIB_4AADBA96B8DD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Périodique
Antimicrobial agents and chemotherapy
ISSN
1098-6596 (Electronic)
ISSN-L
0066-4804
Statut éditorial
Publié
Date de publication
18/07/2023
Peer-reviewed
Oui
Volume
67
Numéro
7
Pages
e0033923
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The impact of broad-spectrum β-lactamases on the susceptibility to novel β-lactamase/β-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic antibacterial activity of zidebactam. Cefepime-taniborbactam showed excellent activity against recombinant E. coli strains, including metallo-β-lactamase producers, whereas aztreonam-avibactam remained the best therapeutic option against class B β-lactamase-producing P. aeruginosa.
Mots-clé
Cefepime/pharmacology, beta-Lactamase Inhibitors/pharmacology, Meropenem/pharmacology, beta-Lactams/pharmacology, Aztreonam/pharmacology, Imipenem, Pseudomonas aeruginosa/genetics, Escherichia coli/genetics, beta-Lactamases/genetics, Anti-Bacterial Agents/pharmacology, Azabicyclo Compounds/pharmacology, Microbial Sensitivity Tests, avibactam, enmetazobactam, nacubactam, relebactam, susceptibility testing, taniborbactam, vaborbactam, zidebactam, β-lactamase
Pubmed
Web of science
Création de la notice
05/06/2023 8:07
Dernière modification de la notice
28/10/2023 6:11
Données d'usage
